Original news and analysis on international IP policy
World Health Organization Director General Margaret Chan today issued a statement attempting to clarify the UN agency's relationship with the industries - like producers of junk food and soda - in line to be regulated as the UN moves to battle globally rising noncommunicable diseases (NCDs) like diabetes, heart disease and cancer.
The recent Internet Governance Forum in Baku, Azerbaijan was used as a stage for some very targeted messages on the upcoming World Conference on International Telecommunication, it saw yet another round of exchanges on some of the tough questions of digital society from privacy and security to future copyright, and had the most intensive discussions on human rights in cyberspace so far.
The director of the Library of Alexandria, Egypt, invited to speak about innovation and food security at the World Intellectual Property Organization last week, said science should reach small farmers in order face the challenge of global food security and increase agricultural yields. He also called for the IP regime to be tailored to serve that purpose.
Richard Elliott writes: Canada’s Access to Medicines Regime (CAMR) was a unanimous pledge by Parliament to help people dying in developing countries because they lack access to affordable medicines. So far, it has delivered only one medicine to one country since Parliament created it more than 8 years ago (in May 2004). CAMR is clearly not working; it needs to be reformed to address the unnecessary deficiencies and limitations that have rendered it cumbersome and user-unfriendly for both developing countries and the manufacturers of lower-cost, generic medicines - the two parties that need to make use of CAMR if patients are to get the medicines they need.
Delegates meeting this week to assess how the World Intellectual Property Organization is instilling a development dimension in its activity had to tackle a marathon session with a large agenda, many projects to assess, and some issues regarding the mandate of the committee. Divergence remained on the agenda of the week but countries agreed on some items, including the convening of a conference on intellectual property and development in 2013.
A study compiling the results of two surveys on the need for reform of United Nations development activities was presented this week in the presence of US and Indian ambassadors who agreed on needed improvements, though with a North and South perspective.
The ETC Group has issued a warning that "agribusiness giants Monsanto, DuPont and Dow are plotting the boldest coup of a global food crop in history," as they have applied to the Mexican government for the planting of transgenic maize on 2,500,000 hectares, approximately the size of El Salvador.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria appointed Ambassador Mark Dybul, a former US Global AIDS Coordinator, as the new head of the organisation. Additionally, the Board decided to move forward on implementing a new funding model, replacing the rounds-based system.
As governments prepare to debate the European Union's overall budget for 2014-2020, European Parliament members and top scientists today warned that any cuts to research and innovation funding will risk the loss of a generation of scientists just when Europe needs them most.
The development dimension of the World Intellectual Property Organization is under scrutiny by member states this week, and after a smooth start and a general commitment to work cooperatively and constructively, discussions have demonstrated strongly held positions, leaving countries to try and find common ground.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain.
Greg Perry, a longtime leader in the European generics industry, has been named the new executive director of the Medicines Patent Pool, a cutting-edge Geneva-based group working to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries.